Clinical Trials Logo

NSCLC Stage IIIB~IV clinical trials

View clinical trials related to NSCLC Stage IIIB~IV.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04147351 Active, not recruiting - NSCLC Stage IIIB~IV Clinical Trials

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Start date: April 10, 2020
Phase: Phase 2
Study type: Interventional

using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.